Aviva interims - Theodosian Capital15 Aug 2025 13:48
AV/ - Strong interims, bright future
Aviva released a good set of H1 results on Thursday. These cover performance to the end of June, so pre-date the closing of the Direct Line acquisition on 1 July. In the period, operating profit of £1.1bn was +22%; SII OFG of £0.9bn was +20%; the COR improved 80bps y/y to 94.6%; and the Solvency II cover ratio of 206% is +3pc YTD. The Solvency II ROE was 16.7%, up 430bps y/y, while the IFRS ROE of 20.6% is +580bps y/y. An interim dividend of 13.1p has been declared, +10% y/y, with guidance maintained for MSD growth in DPS beyond FY 2025, alongside a post 2025 “cadence of regular and sustainable capital returns…at an increased level to reflect the higher share count following the Direct Line acquisition”. As the CEO says, “trading has been very good right across Aviva”. Some metrics to evidence this include growth of 16% in net flows (to £5.8bn) in its leading UK wealth franchise (£209bn of AUM); general insurance sales were +7% and operating profit +29%; and health in-force premiums were +14%. The closing of the DLG acquisition is transformational for the Group, which now has 21m UK customers (4 in 10 adults), with material cross-selling opportunity. An “In Focus” event in November will provide further details on the integration of DLG and its impact to the Group’s targets. Stepping back, the Group now has >70% of operating profit coming from capital-light businesses, with diversified earnings across geographies and product lines and huge scale. There is a huge value creation opportunity here as it integrates DLG; unlocks efficiencies in revenue (cross-selling) and cost; sharpens its portfolio (surely a sale of the non-core India and China units – and the unlocking of the capital tied up in these units – is going to be on the cards in the not too distant future); and, from 2026 onwards, shrinks the share count. AV/ has had a very good run of late, but at 12.5x forward earnings (per Koyfin) it is not expensive here.